


PRODUCT INFORMATION



Remogliflozin etabonate

Item No. 14341

CAS Registry No.: 442201-24-3
Formal Name: 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, β -D-glucopyranoside 6-(ethyl carbonate)
Synonym: GSK189075
MF: C₂₆H₃₈N₂O₉
FW: 522.6
Purity: \geq 98%
Supplied as: A solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Remogliflozin etabonate is supplied as a solid. A stock solution may be made by dissolving the remogliflozin etabonate in the solvent of choice, which should be purged with an inert gas. Remogliflozin etabonate is soluble in methanol and DMSO.

Description

Remogliflozin etabonate is a prodrug form of the sodium-glucose transporter 2 (SGLT2) inhibitor remogliflozin A (Item No. 14340).¹ Remogliflozin etabonate inhibits human SGLT2 and SGLT1 (K_i s = 1.95 and 43.1 μ M, respectively). It inhibits increases in plasma glucose levels in a glucose tolerance test in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104) when administered at doses of 3 and 10 mg/ml. Remogliflozin etabonate (10 and 30 mg/kg twice per day for 6 weeks) also increases fasting plasma insulin levels and reduces fasting plasma glucose and triglyceride levels, as well as urinary glucose excretion, in a *db/db* mouse model of diabetes with hyperinsulinemia and obesity.

Reference

1. Fujimori, Y., Katsuno, K., Nakashima, I., *et al.* Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. *J. Pharmacol. Exp. Ther.* **327**(1), 268-276 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/20/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM